See the DrugPatentWatch profile for janumet
What is Janumet XR, and what is it used for?
Janumet XR is a prescription medicine that combines two drugs used to improve blood sugar control in adults with type 2 diabetes. It’s an “extended-release” (XR) version, meaning the medication is designed to release more slowly over time rather than all at once.
It’s typically used when blood sugar is not controlled well enough with diet, exercise, and/or other diabetes medications, as directed by a clinician.
What drugs are in Janumet XR?
Janumet XR contains:
- Metformin (extended-release)
- Sitagliptin (a DPP-4 inhibitor)
Metformin helps reduce glucose production by the liver and improves insulin sensitivity, while sitagliptin helps increase incretin levels, which increase insulin release and decrease glucagon levels after meals.
How is it different from regular Janumet?
“XR” indicates extended-release dosing. Compared with non-XR formulations, the XR version is designed to provide a different release profile over the day, which can affect dosing frequency and how the tablet is taken.
Who can take it (and who should avoid it)?
Janumet XR is for adults with type 2 diabetes. It’s generally not used for type 1 diabetes or diabetic ketoacidosis. Use and eligibility can depend on kidney function and other health conditions, since metformin-containing products are particularly tied to renal safety.
What side effects do people commonly ask about?
Patients often ask about side effects typical of metformin and sitagliptin, which can include gastrointestinal symptoms such as nausea, diarrhea, or stomach upset. As with other diabetes medicines, clinicians also monitor for uncommon but serious risks, depending on a patient’s specific health profile.
Where can I check patents or competition for Janumet XR?
DrugPatentWatch.com tracks patent-related information for branded products and can be useful if you’re researching exclusivity or generic/biosimilar timelines. You can search Janumet XR on DrugPatentWatch.com here: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/